Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Ana M. Bea"'
Autor:
Victoria Marco-Benedí, Ana M. Bea, Ana Cenarro, Estíbaliz Jarauta, Martín Laclaustra, Fernando Civeira
Publikováno v:
Lipids in Health and Disease, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Background Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by high low-density lipoprotein cholesterol (LDLc) and a high risk of premature cardiovascular disease (CVD). The molecular bases have been well de
Externí odkaz:
https://doaj.org/article/d895cb040eaa42aa834a09f4b5eb070e
Autor:
Lucía Baila-Rueda, Itziar Lamiquiz-Moneo, Estíbaliz Jarauta, Rocío Mateo-Gallego, Sofía Perez-Calahorra, Victoria Marco-Benedí, Ana M. Bea, Ana Cenarro, Fernando Civeira
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background Familial hypercholesterolemia (FH) is a genetic disorder that result in abnormally high low-density lipoprotein cholesterol levels, markedly increased risk of coronary heart disease (CHD) and tendon xanthomas (TX). However, the cl
Externí odkaz:
https://doaj.org/article/07a7ade516274cedb4478a33dc025869
Autor:
Itziar Lamiquiz-Moneo, Ana M. Bea, Cristian Palacios-Pérez, Pilar De Miguel-Etayo, Esther M. González-Gil, Chuan López-Ariño, Fernando Civeira, Luis A. Moreno, Rocio Mateo-Gallego
Publikováno v:
Cells, Vol 9, Iss 3, p 693 (2020)
Introduction: The global prevalence of type 2 diabetes (T2D) is increasing rapidly, especially in low- and middle-income countries and has a high number of associated comorbidities. Plasmatic concentrations of branched chain amino acids (BCAA) and re
Externí odkaz:
https://doaj.org/article/f538004fd02d4b2182df08296e7a05f4
Autor:
Ana M. Bea, Asier Larrea-Sebal, Victoria Marco-Benedi, Kepa B. Uribe, Unai Galicia-Garcia, Itziar Lamiquiz-Moneo, Martín Laclaustra, Belén Moreno-Franco, Pablo Fernandez-Corredoira, Salvador Olmos, Fernando Civeira, César Martin, Ana Cenarro
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 43:1066-1077
Background: apo (apolipoprotein) E has crucial role in lipid metabolism. The genetic variation in APOE gene is associated with monogenic disorders and contributes to polygenic hypercholesterolemia and to interindividual variability in cholesterol. AP
Autor:
Ana M Bea, Ana Cenarro, Victoria Marco-Bened, Martn Laclaustra, Csar Martn, Daiana Ibarretxe, Xavier Pint, Teresa Arrobas, Clara Vials, Fernando Civeira, Salvador Olmos
Publikováno v:
Clinical Chemistry. 69:140-148
Background Familial dysbetalipoproteinemia (FDBL) is a monogenic disease due to variants in APOE with a highly variable phenotype. Current diagnostic lipid-based methods have important limitations. The objective is twofold: to define characteristics
Autor:
Victoria Marco-Benedí, Ana M. Bea, Rosa M. Sánchez Hernández, Núria Plana, Pedro Valdivielso, Fernando Civeira
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 34:303-310
Autor:
Rocío Mateo-Gallego, Sofía Pérez-Calahorra, Ana M. Bea, Irene Gracia-Rubio, Carmen Rodrigo-Carbo, Belen Moreno-Franco, Fernando Civeira, Martín Laclaustra, Itziar Lamiquiz-Moneo
Publikováno v:
Clínica e Investigación en Arteriosclerosis.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 33:50-55
Dysbetalipoproteinaemia (or type III hyperlipoproteinaemia) is a severe mixed hyperlipidaemia resulting from the accumulation of remnant chylomicron and VLDL particles in plasma, also called β-VLDL. It is caused by a defect in the recognition by hep
Autor:
Núria Plana, Ana M. Bea, Martín Laclaustra, Ángel Brea, Rosa M. Sánchez-Hernández, Victoria Marco-Benedí, Manuel Suárez-Tembra, Fernando Civeira, Xavier Pintó
Publikováno v:
Atherosclerosis. 320:47-52
Background and aims Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by a high risk of cardiovascular disease when not in lipid-lowering treatment. However, there is a large variability in the clinical presentation i